Country Daily
Macau Gaming / Pateo Connect Technology / Sino Land / The United Laboratories International
Analyst
Key Indices
Top Stories
Sector Update | Macau Gaming
Macau’s Aug 26 GGR reached MOP21.9b, down 1% yoy but up 8% mom, as July was impacted by the FIFA World Cup. August’s GGR figure missed market consensus by 2%, and recovered to 90% of 2019’s level. 8M26 GGR rose 4% yoy to MOP169.1b. Macau’s July visitation reached 3.5m, up 2% yoy and 26% mom, broadly in line with 2019’s level. For 7M26, cumulative visitation increased 8% yoy to 24.5m, up 3% vs 2019’s level. Maintain OVERWEIGHT; top pick: Galaxy.
Company Results | Pateo Connect Technology (2889 HK/BUY/HK$147.90/Target: HK$350.00)
1H26 results met estimates with revenue up 105% yoy to Rmb2,228m and adjusted net loss down 36% yoy to Rmb103m. GAAP net loss increased 34.5% yoy to Rmb306m, due to share-based compensation. We keep our 2026 adjusted net loss estimate, and lift 2027-28 adjusted net profit projections by 6%/3% respectively to factor in the acquisition of CME. Maintain BUY with a target price of HK$350.00.
Company Results | Sino Land (83 HK/BUY/HK$10.26/Target: HK$14.00)
Sino Land’s FY26 underlying profit fell 6.4% yoy to HK$4.79b, in line with consensus and 2.3% above our forecast. DPS was maintained at HK$0.58, implying a 113.7% payout ratio. With a strengthened net cash position, the company is selectively pursuing Hong Kong land acquisitions. The leasing momentum is improving in office and residential, while retail tenant-mix optimisation continues. Maintain BUY and raise our target price to HK$14.00.
Company Results | The United Laboratories International (3933 HK/BUY/HK$8.20/Target: HK$11.00)
TUL’s 1H26 results missed as a lapse in licence income resulted in a significant decrease in revenue and margins. Excluding licence income, overall operations remained stable in 1H26. We expect revenue and earnings to resume steady growth in 2H26, supported by a low bulk-medicine price base and continued finished-product expansion, while new product launches should further enrich the portfolio and generate significant revenue streams from 2027. Maintain BUY with a lower target price of HK$11.00.
Top Stories
Sector Update | Macau Gaming
Macau’s Aug 26 GGR reached MOP21.9b, down 1% yoy but up 8% mom, as July was impacted by the FIFA World Cup. August’s GGR figure missed market consensus by 2%, and recovered to 90% of 2019’s level. 8M26 GGR rose 4% yoy to MOP169.1b. Macau’s July visitation reached 3.5m, up 2% yoy and 26% mom, broadly in line with 2019’s level. For 7M26, cumulative visitation increased 8% yoy to 24.5m, up 3% vs 2019’s level. Maintain OVERWEIGHT; top pick: Galaxy.
Company Results | Pateo Connect Technology (2889 HK/BUY/HK$147.90/Target: HK$350.00)
1H26 results met estimates with revenue up 105% yoy to Rmb2,228m and adjusted net loss down 36% yoy to Rmb103m. GAAP net loss increased 34.5% yoy to Rmb306m, due to share-based compensation. We keep our 2026 adjusted net loss estimate, and lift 2027-28 adjusted net profit projections by 6%/3% respectively to factor in the acquisition of CME. Maintain BUY with a target price of HK$350.00.
Company Results | Sino Land (83 HK/BUY/HK$10.26/Target: HK$14.00)
Sino Land’s FY26 underlying profit fell 6.4% yoy to HK$4.79b, in line with consensus and 2.3% above our forecast. DPS was maintained at HK$0.58, implying a 113.7% payout ratio. With a strengthened net cash position, the company is selectively pursuing Hong Kong land acquisitions. The leasing momentum is improving in office and residential, while retail tenant-mix optimisation continues. Maintain BUY and raise our target price to HK$14.00.
Company Results | The United Laboratories International (3933 HK/BUY/HK$8.20/Target: HK$11.00)
TUL’s 1H26 results missed as a lapse in licence income resulted in a significant decrease in revenue and margins. Excluding licence income, overall operations remained stable in 1H26. We expect revenue and earnings to resume steady growth in 2H26, supported by a low bulk-medicine price base and continued finished-product expansion, while new product launches should further enrich the portfolio and generate significant revenue streams from 2027. Maintain BUY with a lower target price of HK$11.00.
Analyst
Key Indices
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
